XTX Topco Ltd Buys 68,245 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

XTX Topco Ltd increased its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 177.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 106,773 shares of the biopharmaceutical company's stock after purchasing an additional 68,245 shares during the quarter. XTX Topco Ltd's holdings in Amicus Therapeutics were worth $871,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Virtus Fund Advisers LLC acquired a new position in Amicus Therapeutics in the 4th quarter valued at about $29,000. Covestor Ltd raised its stake in Amicus Therapeutics by 114.9% in the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after purchasing an additional 2,312 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in Amicus Therapeutics in the 4th quarter worth about $59,000. GAMMA Investing LLC boosted its holdings in shares of Amicus Therapeutics by 1,610.8% in the 1st quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company's stock valued at $61,000 after purchasing an additional 7,007 shares during the last quarter. Finally, Bryce Point Capital LLC purchased a new position in Amicus Therapeutics in the first quarter valued at approximately $100,000.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Wall Street Zen upgraded Amicus Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. UBS Group lifted their price target on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. The Goldman Sachs Group decreased their target price on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a report on Friday, May 2nd. Finally, Morgan Stanley raised shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research report on Thursday, July 17th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Amicus Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $16.22.

Amicus Therapeutics Price Performance

FOLD stock traded down $0.18 during trading on Thursday, hitting $6.76. 2,278,475 shares of the stock traded hands, compared to its average volume of 3,865,655. The stock has a market cap of $2.08 billion, a price-to-earnings ratio of -56.37 and a beta of 0.53. The company has a current ratio of 3.21, a quick ratio of 2.29 and a debt-to-equity ratio of 1.92. Amicus Therapeutics, Inc. has a one year low of $5.51 and a one year high of $12.65. The company has a 50 day simple moving average of $6.10 and a 200 day simple moving average of $7.40.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.